Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clin Cancer Res. 2020 01 15; 26(2):354-363.

View in: PubMed

subject areas

Adult
Aged
Biomarkers, Tumor
Breast Neoplasms
Estrogen Receptor alpha
Female
Gene Amplification
Humans
Middle Aged
Molecular Targeted Therapy
Naphthalenes
Neoplasm Metastasis
Patient Safety
Protein Kinase Inhibitors
Quinolines
Receptor, ErbB-2
Receptor, Fibroblast Growth Factor, Type 1
Receptors, Progesterone
Treatment Outcome

authors with profiles

Alexander Pearson